Cipla reported 20.24B in Cost of Sales for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Cipla CIPLA:IN 20.24B 1.22B
Dr.Reddys Laboratories DRRD:IN 19.11B 135M
Sun Pharmaceuticals SUNP:IN IR 29002M 3605.7M
UPL UPLL:IN 46.64B 33.3B